Evidence map›Paper›PMID 28092287›Full record

ReviewCurrent opinion in allergy and clinical immunology2017

Current and future management of the young child with early onset wheezing.

Allison J Burbank, Stanley J Szefler

Open access · greenAbstract readReview
In one paragraph

Review in Current opinion in allergy and clinical immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Severe bronchiolitis profiles and risk of recurrent wheeze by age 3 years.The Journal of allergy and clinical immunology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Allison J BurbankaUniversity of North Carolina, Chapel Hill, North Carolina bChildren's Hospital Colorado, Aurora, Colorado, USA.
Stanley J Szefler
University of Colorado Denver · USUniversity of North Carolina at Chapel Hill · US

Funding

UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program-Evaluation SupplementT32GM086330 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KIM L.R. BROUWER, Daniel Gonzalez · 2011 to 2026
$8.5M
Clinical Centers for the NHLBI Asthma Network (AsthmaNet)U10HL098075 · NHLBI · NATIONAL JEWISH HEALTH · PI SZEFLER, STANLEY J., WECHSLER, MICHAEL E · 2009 to 2015
$5.1M
NHLBI NIH HHS U10 HL098075NIGMS NIH HHS T32 GM086330
6 · The paper itself

Abstract

purpose of reviewIn this review, we discuss current thinking in relation to available guidelines for the care of preschool-aged children with recurrent wheezing, while highlighting the gaps in our knowledge and discussing changes that could occur over the next 5 years. RECENT

findingsThe Asthma Predictive Index as well as allergen-specific IgE, peripheral eosinophil count and exhaled nitric oxide are perhaps underutilized sources of information that can assist in predicting progression to asthma and response to therapies. Inhaled corticosteroids and leukotriene receptor antagonists decrease impairment and exacerbation frequency in wheezing children but are not disease modifying. Macrolides may be useful during acute wheezing episodes for preventing progression to more severe symptoms. Monoclonal antibodies targeting IgE and TH2 cytokines have been successful in trials of adults and older children with asthma, but trials in younger children are needed. SUMMARY: Establishing the phenotype and endotype of young wheezing children can be useful for prognostication of future asthma risk as well as for selection of the most appropriate treatment. Primary asthma prevention strategies are needed during the critical developmental window in early life prior to the onset of irrecoverable loss of lung function.

Indexed as

Respiratory SoundsAdultAge of OnsetAnimalsAsthmaChild, PreschoolCytokinesDisease ManagementHumansImmunoglobulin EImmunotherapyPractice Guidelines as TopicPrognosisRiskTh2 CellsCytokinesImmunoglobulin E

Identifiers

PMID28092287
PMCPMC5550831
OpenAlexW2577080516

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.